For the first time, researchers have succeeded in passing an antibody through the blood-brain barrier to act as a tracer for PET imaging of the brain, resulting in more precise information being obtained than with regular radioactive tracers. The study provides hope for more effective diagnosis of early onset Alzheimer's disease and improvements in monitoring the effects of medication.
"The major advantage of monoclonal antibodies compared to regular small molecule PET tracers is their very high specificity. Our antibody binds soluble forms of amyloid beta, so-called protofibrils, which are probably the toxic form of amyloid and which cause the symptoms," says Lars Lannfelt, professor of Geriatrics at Uppsala University.
The researchers are currently working on a similar PET method for Parkinson's disease, it is expected that it will be possible to examine other brain conditions using these techniques, for example, depression and bipolar disorder.
Keywords: Alzheimers; Brain scans; Diagnosis.Complete article can be read at http://www.eurekalert.org/pub_releases/2016-02/uu-apa021816.php